https://www.selleckchem.com/products/rvx-208.html
5months after obinutuzumab injection. After median follow-up 20.3months (IQR 11.5-22.6), 5/14 patients relapsed including 4 within 100days following B cell repletion. Relapse-free survival was 60% at 24months from obinutuzumab infusion. Mild infusion reactions were reported in 3/14 patients during obinutuzumab and 4/14 during daratumumab infusions. Mild transient neutropenia (500-1000/mm ) occurred in 2/14 patients. Intravenous immunoglobulins were given to 12/14 patients due to hypogammaglobulinemia. Low IgA and IgM levels were noted i
Like
Comment
Share
